TickerFacts.

Cullinan Therapeutics, Inc. (CGEM): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$241.34M
Year ended 2025-12-31
-$221.49M
Trailing 12 months to 2026-06-30
$144.74M2020-12-31: -$60.27M2021-12-31: -$67.90M2022-12-31: $144.74M2023-12-31: -$190.78M2024-12-31: -$196.61M2025-12-31: -$241.34M-$241.34M
2020-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$241.34Mn/m2026-03-10, From 2025-01-01
2024-12-31-$196.61Mn/m2026-03-10, From 2024-01-01
2023-12-31-$190.78Mn/m2025-02-27, From 2023-01-01
2022-12-31$144.74Mn/m2024-03-14, From 2022-01-01
2021-12-31-$67.90Mn/m2023-03-09, From 2021-01-01
2020-12-31-$60.27Mn/a2022-03-17, From 2020-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Cullinan Therapeutics, Inc. (CGEM)2025-12-31-$241.34Mn/m
REGENXBIO Inc. (RGNX)2025-12-31-$145.58Mn/m
Allogene Therapeutics, Inc. (ALLO)2025-12-31-$196.96Mn/m
Vericel Corp (VCEL)2025-12-31$22.59M+125.4%
Scholar Rock Holding Corp (SRRK)2025-12-31-$382.99Mn/m
ImmunityBio, Inc. (IBRX)2025-12-31-$240.50Mn/m
Adaptive Biotechnologies Corp (ADPT)2025-12-31-$41.12Mn/m
BioCryst Pharmaceuticals Inc (BCRX)2025-12-31$342.38Mn/m
Scilex Holding Co (SCLX)2025-12-31-$341.38Mn/m

Compare CGEM, RGNX, ALLO, VCEL side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗